Exelixis, Teva settle Cabometyx patent litigation with 2031 generic license

With stalwart cancer drug Cabometyx driving its commercial performance, Exelixis has put plenty of effort behind defending the drug's intellectual property. Now, a patent deal with generics giant Teva adds one more layer to its defenses.